Ronnie of I'm Oncology. Morris, morning. Champions CEO Good
CFO. David for year-end Joining is our XXXX Thank call. fiscal me today our Miller, you for joining earnings us
forward-looking remind results actual differ materially described I'll begin, and is could you what those I today's call I'll be Before making in statements from during that that statements.
during on available of XX-Q discussed Form XX-K. Reconciliation call in the may factors financial the and the could that results cause financial available that information GAAP our Additional to is measures non-GAAP measures differ to in release. Form be is earnings
we progress, longer-term strategy and embark on and evolve business Overall, key I year transformational another continuing deliver as we times. and had to of our strategy. successfully expanding to on exciting while capabilities, significant some would our our on like core in
Since Champions, the that the clear value data appreciation were within a building. for had set the rare we inception contained we of
several Our tumor the create information we bank unique and reasons. for are
other First, data sets research, within provide This the that tumor of insights. our means relevant a using clinical unlike our present and representative highly models more established models tumors most are setting. models in accurate used
have bank tumor, a Second, using to a that living of characterization. source allowing level deep perpetual PDX our models means tumor we for a approach and a of of continuous
also tumors Specifically, multiple the we characterize using these drugs same newly with can these We fully reinterrogate establish of multiple or approved can drug drug response methods. the data sets molecular tumor from analytical tumors or nature combinations.
new data existing we optimized, as analysis, this acquire emerge can and information. are technologies integrate our or such new As into proteomic
by bank tumors simulate models. otherwise been phenotypic, information behind in models, molecular with therapeutic our a services we services. produce important tumor value has of the ability leveraging and living tumor business. have of scenarios response elements by tumor the that can manipulate combination of other The information unique our we PDX grow our key and aggressively growth combined these and a proven Third, in excellence been are operational This unavailable to our genotypic or bank
companies and drug on created pharmaceutical More preclinical have of in subpopulations mechanisms biotech targets, of information look and settings both thousands their identify for for programs. early identify for than used to studies. signs and of used data XXX clinical the They and them we for have across action efficacy, look relied
always becoming business on data we laser-focused services set was a and platform expanding company. the knew that being a mass and unique we valuable, our profitable While were
data proteomic, that providing business is businesses new the to scientists information. revolutionary that After in leverage at started insights analyzing achieving accelerate derive from and growth. last higher-value, We gain rollout platform discovery the us transition additional and PDX a novel our our of software customers transcriptomic information a long-term additional models of with profitability, Lumin would for ability sets profit allow their data genomic we this capable would our value with allow fingertips. to looking interpretation higher-margin started that year in would real-time, revenue to
XX,XXX to as available not that sets ability our any assembled the explore well The PDX data in in of power data set. public models responses are cancer thousands is includes as over treatment clinical Lumin from of that data
that companies visualization been range and analysis platform's the platform model this has We drug have large development. customers uptake using Both the in been in have all exciting. are licensing to stages this represented used customers a small SaaS and of our tools and of
targets. relies learning capabilities. to use able This the characterized and team, tools, therapeutic and using Lumin information deeply to our been on of analytical algorithms, target sets set our have AI data in-house power combined developed heavily data we expertise machine to the computational our which discovery demonstrate To discover interrogate has novel Lumin's
a of as time target new and approach required emerged the discovery in target for drug has scale reduce to have discovery central the increases years. which approaches initiated. recent the mechanism for programs potential This Computational be can
However, the set data these mining. is suffer for available poor computational underlying from that quality approaches of often
leverages is derived complete that more from authentic a data heterogeneity. biology of Our computational and tumor cell approach set a more models tumor
As identified our missed analysis other computational when data overlooked are targets a using result, that or sets.
advancing the interesting plan bring the computationally the platform We targets and targets them. X we validated also we To to to our to than process date, over and targets, some validate to preclinical labs invest extensive us million The in $X years of through these stage. in pipeline. are those development and more of derived next efficiently forward available $X allows the quickly between take targets million X have and IND-enabling the
and We end. partner, novel far the have royalty on want forward could with generate which internal these partnering, licensing Depending advance milestone upfront options think compound back finding a on we to development. we targets, include a or take payments payments many before to each how compound
this received but in interest early from we still are discussions is have process, partners potential the with We the exciting.
of we due have in business, which investments to Lumin While to continue R&D the increased services made grow development continued of the the software. and addition discovery our the targets to of spending, our plan therapeutic to profitability validation we in primarily is
capture oncology business business this into experimental data proprietary a platforms. world-leading company To we of that In based data model a value ecosystem our off centered we transformation, research the unique units, effect more the our center the reorganized and summary, is around create. that are dynamic we evolving from to of
focus to continue core about excited We our growing be and services business.
an SaaS have initiative. we our In added addition drug innovative to and services discovery an AI-powered target business business,
growing the potential opportunities the stages, in in excitement throughout organization. are new still are they and early both While
a detailed me call to Miller of financial more over turn the let David for Now results. review the
